Soliris

3d illustration of human body eye anatomy

A Novel Treatment Approach for Acute Relapses of NMOSD Shows Promise

Eculizumab may be an effective treatment for acute episodes of neuromyelitis optica spectrum disorder (NMOSD), according to a study recently published in Frontiers in Neurology. “Given that disease burden and mortality in NMOSD is almost entirely related to relapses, increased use of eculizumab acutely could potentially aid recovery from an attack in very severe attacks,…

anemia

Factor D Inhibition Shows Therapeutic Potential in CAD

Researchers wrote a review discussing current novel insights into the use of factor D inhibition in a number of complementopathies, including cold agglutinin disease (CAD), and published their findings in the International Journal of Molecular Sciences.  Complement-mediated diseases are scattered across the various medical disciplines, including hematology, rheumatology, and nephrology. Much research has been devoted…

injection

Eculizumab Leads to Clinical Improvements in MG Study

Eculizumab treatment leads to clinical improvements in most patients with generalized myasthenia gravis (MG), according to a new study published in Muscle and Nerve. Moreover, the treatment had a favorable safety profile even when combined with other immunosuppressants. Because the safety of eculizumab in patients with generalized MG in clinical practice is limited and because…

world map

Eculizumab Well Tolerated and Effective in Broad Spectrum of MG, Study Finds

Eculizumab was well tolerated and effective in a wide spectrum of Japanese patients with generalized myasthenia gravis (MG) who were anti-acetylcholine receptor antibody-positive (AChR Ab+) and had a disease that was difficult to control, according to a new study published in Clinical and Experimental Neuroimmunology.  Eculizumab is an inhibitor of the complement protein C5 that…

COVID19

CAD Secondary to SARS-CoV-2 Treated With Eculizumab: A Case Report

Researchers reported a case of cold agglutinin disease (CAD) occurring secondary to severe SARS-CoV-2 infection that was treated with eculizumab and published their findings in BMJ Case Reports. They showed that the eculizumab therapy quasi-resolved the hemolysis, but ultimately the patient died of the COVID-19 infection. “Secondary CAD can be related to hematological or infectious…

nerve cells

Real-World Evidence Supports Eculizumab for Refractory Anti-AChR MG

Real-world evidence supports the use of eculizumab (Soliris®) for the treatment of refractory, anti-acetylcholine receptor (AChR)-antibody (ab) positive myasthenia gravis (MG), as published in the Journal of Neurology, Neurosurgery, and Psychiatry. Eculizumab excelled rituximab in the treatment of generalized, therapy-refractory anti-AChR-ab positive MG, according to findings from a new retrospective, observational multicentric analysis of patients…

synapse

New Assay Studies Complement-Mediated Synaptic Damage in Myasthenia Gravis

Researchers developed a new bioassay to study complement-mediated synaptic damage in neuromuscular junctions (NMJs) of patients with myasthenia gravis (MG). “The strict spatial restriction of the complement activation at the native NMJ makes our new model highly relevant for MG,” said the authors of the new study published in the Journal of Neuroscience Methods. They…

Next post in MG News Briefs